High Court Decision Seen Enhancing India’s Drug Controls
This article was originally published in PharmAsia News
Executive SummaryGovernment legal experts in India say a recent Delhi High Court decision could have a major impact on the drug industry's ability to set prices and protect patents. Regulatory authorities read the court's decision to mean access to affordable drugs is a fundamental right of Indians. The National Pharmaceutical Pricing Authority says the decision supports its effort to impose universal price controls on all drugs considered essential. The decision also is seen in some quarters as authorizing the government to impose compulsory licensing arrangements so generics can be available. (Click here for more
You may also be interested in...
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.